Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1

Yoshiaki Iwasaki, Ryo Ichi Okamoto, Yasushi Ishii, Yasuyuki Araki, Noriaki Hashimoto, Kazuhide Yamamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Elderly patients with chronic hepatitis C cannot tolerate standard combination therapy of peginterferon and ribavirin, which remains the backbone of therapy in many countries, including Japan. The efficacy and safety of low-dose peginterferon α-2b in combination with low and escalating doses of ribavirin in older patients with high viral load genotype 1 were investigated in this randomized controlled trial. Thirty-two patients (age ≥60 years) were randomized into standard (group 1) or low (group 2) doses of peginterferon α-2b in combination with low and escalating doses of ribavirin. Patients were evaluated for safety and efficacy of treatment. There was a higher virological response rate in group 1 than in group 2. However, the response in men was higher than in women in the early treatment phase and 24 weeks after treatment (P=0.008). There was no significant difference between the two groups in the virological response rate in men and women. Completion of therapy was higher in group 2 than in group 1 (31% vs. 13%, P=0.200). Dose modification of ribavirin was less frequent in group 2 than in group 1 (69% vs. 88%, P=0.200). These data suggest that combination therapy with low-dose peginterferon plus low and escalating doses of ribavirin may be safer in older patients than that with standard dose peginterferon, without impairing the treatment response.

Original languageEnglish
Pages (from-to)2082-2089
Number of pages8
JournalJournal of Medical Virology
Volume87
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Ribavirin
Chronic Hepatitis C
Viral Load
Genotype
Therapeutics
Safety
Japan
Randomized Controlled Trials

Keywords

  • Adverse event
  • Dose modification
  • Sustained virological response
  • Treatment discontinuation

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1. / Iwasaki, Yoshiaki; Okamoto, Ryo Ichi; Ishii, Yasushi; Araki, Yasuyuki; Hashimoto, Noriaki; Yamamoto, Kazuhide.

In: Journal of Medical Virology, Vol. 87, No. 12, 01.12.2015, p. 2082-2089.

Research output: Contribution to journalArticle

Iwasaki, Yoshiaki ; Okamoto, Ryo Ichi ; Ishii, Yasushi ; Araki, Yasuyuki ; Hashimoto, Noriaki ; Yamamoto, Kazuhide. / Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1. In: Journal of Medical Virology. 2015 ; Vol. 87, No. 12. pp. 2082-2089.
@article{84acc28fc20841d8a462e3736f626159,
title = "Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1",
abstract = "Elderly patients with chronic hepatitis C cannot tolerate standard combination therapy of peginterferon and ribavirin, which remains the backbone of therapy in many countries, including Japan. The efficacy and safety of low-dose peginterferon α-2b in combination with low and escalating doses of ribavirin in older patients with high viral load genotype 1 were investigated in this randomized controlled trial. Thirty-two patients (age ≥60 years) were randomized into standard (group 1) or low (group 2) doses of peginterferon α-2b in combination with low and escalating doses of ribavirin. Patients were evaluated for safety and efficacy of treatment. There was a higher virological response rate in group 1 than in group 2. However, the response in men was higher than in women in the early treatment phase and 24 weeks after treatment (P=0.008). There was no significant difference between the two groups in the virological response rate in men and women. Completion of therapy was higher in group 2 than in group 1 (31{\%} vs. 13{\%}, P=0.200). Dose modification of ribavirin was less frequent in group 2 than in group 1 (69{\%} vs. 88{\%}, P=0.200). These data suggest that combination therapy with low-dose peginterferon plus low and escalating doses of ribavirin may be safer in older patients than that with standard dose peginterferon, without impairing the treatment response.",
keywords = "Adverse event, Dose modification, Sustained virological response, Treatment discontinuation",
author = "Yoshiaki Iwasaki and Okamoto, {Ryo Ichi} and Yasushi Ishii and Yasuyuki Araki and Noriaki Hashimoto and Kazuhide Yamamoto",
year = "2015",
month = "12",
day = "1",
doi = "10.1002/jmv.24276",
language = "English",
volume = "87",
pages = "2082--2089",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1

AU - Iwasaki, Yoshiaki

AU - Okamoto, Ryo Ichi

AU - Ishii, Yasushi

AU - Araki, Yasuyuki

AU - Hashimoto, Noriaki

AU - Yamamoto, Kazuhide

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Elderly patients with chronic hepatitis C cannot tolerate standard combination therapy of peginterferon and ribavirin, which remains the backbone of therapy in many countries, including Japan. The efficacy and safety of low-dose peginterferon α-2b in combination with low and escalating doses of ribavirin in older patients with high viral load genotype 1 were investigated in this randomized controlled trial. Thirty-two patients (age ≥60 years) were randomized into standard (group 1) or low (group 2) doses of peginterferon α-2b in combination with low and escalating doses of ribavirin. Patients were evaluated for safety and efficacy of treatment. There was a higher virological response rate in group 1 than in group 2. However, the response in men was higher than in women in the early treatment phase and 24 weeks after treatment (P=0.008). There was no significant difference between the two groups in the virological response rate in men and women. Completion of therapy was higher in group 2 than in group 1 (31% vs. 13%, P=0.200). Dose modification of ribavirin was less frequent in group 2 than in group 1 (69% vs. 88%, P=0.200). These data suggest that combination therapy with low-dose peginterferon plus low and escalating doses of ribavirin may be safer in older patients than that with standard dose peginterferon, without impairing the treatment response.

AB - Elderly patients with chronic hepatitis C cannot tolerate standard combination therapy of peginterferon and ribavirin, which remains the backbone of therapy in many countries, including Japan. The efficacy and safety of low-dose peginterferon α-2b in combination with low and escalating doses of ribavirin in older patients with high viral load genotype 1 were investigated in this randomized controlled trial. Thirty-two patients (age ≥60 years) were randomized into standard (group 1) or low (group 2) doses of peginterferon α-2b in combination with low and escalating doses of ribavirin. Patients were evaluated for safety and efficacy of treatment. There was a higher virological response rate in group 1 than in group 2. However, the response in men was higher than in women in the early treatment phase and 24 weeks after treatment (P=0.008). There was no significant difference between the two groups in the virological response rate in men and women. Completion of therapy was higher in group 2 than in group 1 (31% vs. 13%, P=0.200). Dose modification of ribavirin was less frequent in group 2 than in group 1 (69% vs. 88%, P=0.200). These data suggest that combination therapy with low-dose peginterferon plus low and escalating doses of ribavirin may be safer in older patients than that with standard dose peginterferon, without impairing the treatment response.

KW - Adverse event

KW - Dose modification

KW - Sustained virological response

KW - Treatment discontinuation

UR - http://www.scopus.com/inward/record.url?scp=84942983778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942983778&partnerID=8YFLogxK

U2 - 10.1002/jmv.24276

DO - 10.1002/jmv.24276

M3 - Article

C2 - 26010427

AN - SCOPUS:84942983778

VL - 87

SP - 2082

EP - 2089

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 12

ER -